drugset / Trial / NCT07674615
IMMU-132 in TROP-2 Overexpressed Advanced and Relapsed Ovarian Cancer
NaSingle-groupOpen-labelTreatment
Summary
To observe the efficacy and safety of IMMU-132 in patients with advanced or recurrent ovarian cancer with high TROP-2 expression in tumor tissue, who have failed standard therapy or are unable to receive standard treatment.
Timeline
- Start
- 2026-07-01
- Primary completion
- 2027-06-30
- Completion
- 2027-06-30
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Sacituzumab Govitecan | Monoclonal antibody | 10 mg/kg | Intravenous |